Log In
BCIQ
Print this Print this
 

UCART19

  Manage Alerts
Collapse Summary General Information
Company Cellectis S.A.
DescriptionChimeric antigen receptor (CAR)-modified CD19-targeted allogeneic T cells
Molecular Target CD19
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Non-stem cell

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1,048.2M

$48.2M

$1,000.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/19/2015

Undisclosed

Undisclosed

Undisclosed

02/24/2014

$1,048.2M

$48.2M

$1,000.0M

Get a free BioCentury trial today